European Union - Maltese - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - aġenti antineoplastiċi - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

European Union - Maltese - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressanti - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

European Union - Maltese - EMA (European Medicines Agency)

mylan pharmaceuticals limited - rasagiline tartrate - marda ta 'parkinson - mediċini kontra l-parkinson - rasagiline mylan huwa indikat għat-trattament ta ' l-idiopathic parkinson's marda (pd) bħala monotherapy (mingħajr ticlopidine hydrochloride) jew bħala terapija frozen (b ' ticlopidine hydrochloride) fil-pazjenti bl-għan ta ' l-oxxillazzjonijiet ta ' doża.

European Union - Maltese - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - granisetron - vomiting; cancer - anti-emetiċi u anti-nawżjanti, , serotonin (5ht3) antagonisti - prevenzjoni ta 'nawżja u remettar f'pazjenti li qed jirċievu kimoterapija moderata jew ħafna emetogenika, bi jew mingħajr cisplatin, sa ħames ijiem konsekuttivi. sancuso tista'tintuża fil-pazjenti li kienu qed jirċievu l-ewwel kors ta ' kimoterapija jew f'pazjenti li qabel kienu rċivew il-kimoterapija.

European Union - Maltese - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidone - fibrożi pulmonari idjopatika - immunosoppressanti - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

European Union - Maltese - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressanti - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

European Union - Maltese - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulina glargine - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sentejn u aktar.

European Union - Maltese - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - aġenti antineoplastiċi - bħala mediċina weħidha, abraxane hu indikat għall-kura ta ' kanċer metastatiku tas-sider f'pazjenti adulti li jkunu fallew l-kura tal-ewwel linja għall-mard metastatiku u li għalihom standard, terapija li jkun fiha anthracycline ma tkunx indikata. abraxane flimkien ma 'gemcitabine huwa indikat għall-kura tal-ewwel linja ta' pazjenti adulti b'kanċer metastatiku tal-adenokarċinoma tal-frixa. abraxane f'kombinazzjoni ma 'carboplatin huwa indikat għall-kura tal-ewwel linja ta taċ-ċelluli mhux żgħar tal-pulmun il-kanċer fil-pazjenti adulti li mhumiex kandidati għall-potenzjalment kurattiva-kirurġija u/jew terapija ta' radjazzjoni.

European Union - Maltese - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulina glulisine - diabetes mellitus - drogi użati fid-dijabete - trattament ta 'adulti, adoloxxenti u tfal, ta' sitt snin jew aktar b'dijabete mellitus, fejn huwa meħtieġ it-trattament bl-insulina.

European Union - Maltese - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - mard vaskulari periferali - aġenti antitrombotiċi - clopidogrel huwa indikat fl-adulti għall-prevenzjoni ta 'avvenimenti aterotrombotiċi f': pazjenti li jbatu minn infart mijokardijaku (minn ftit jiem sa inqas minn 35 jum), puplesija iskemika (minn 7 ijiem sa inqas minn 6 xhur) jew mard arterjali periferali. - pazjenti li jbatu mis-sindromu koronarju akut: mhux elevazzjoni tas-segment st sindromu koronarju akut (anġina instabbli jew mhux tal-mewġa q 'infart mijokardijaku), li jinkludu pazjenti fi proċess li titpoġġa stent wara intervent koronarju perkutanju, flimkien ma' acetylsalicylic acid (asa). l - elevazzjoni tas-segment st infart mijokardijaku akut, flimkien ma ' asa f'medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika. għall-aktar informazzjoni jekk jogħġbok irreferi għal sezzjoni 5.